Idexx Laboratories IDXX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $4.45B+13.1% | $4.3B+10.4% | $4.17B+8.4% | $4.04B+6.7% | $3.93B+5.6% | ||
| $1.69B+10.8% | $1.64B+8.3% | $1.6B+5.6% | $1.55B+3.6% | $1.52B+2.5% | ||
| $2.76B+14.5% | $2.66B+11.8% | $2.57B+10.2% | $2.48B+8.7% | $2.41B+7.6% | ||
| 62.1%+0.8pp | 61.8%+0.8pp | 61.7%+1.0pp | 61.5%+1.1pp | 61.3%+1.1pp | ||
| $257.93M+14.0% | $251.21M+14.3% | $242.1M+13.2% | $232.67M+11.9% | $226.22M+13.7% | ||
| $662.57M+11.3% | $643.55M+9.4% | $626.6M+8.0% | $613.72M+7.7% | $595.28M+4.9% | ||
| $432.35M-2.1% | $404.79M-8.5% | $397.32M-7.2% | $383.27M-9.9% | $441.83M+23.5% | ||
| $1.35B+7.1% | $1.3B+3.9% | $1.27B+4.2% | $1.23B+2.8% | $1.26B+13.4% | ||
| $1.35B+7.1% | $1.3B+3.9% | $1.27B+4.2% | $1.23B+2.8% | $1.26B+13.4% | ||
| $1.41B+22.7% | $1.36B+20.5% | $1.31B+17.5% | $1.26B+15.9% | $1.15B+2.7% | ||
| 31.6%+2.5pp | 31.6%+2.7pp | 31.3%+2.4pp | 31.1%+2.5pp | 29.1%-0.8pp | ||
| $38.93M+25.7% | $38.85M+24.5% | $37.14M+12.6% | $34.18M+0.8% | $30.96M-14.9% | ||
| $2.39M-74.8% | $3.01M-76.3% | $4.62M-67.3% | $6.76M-46.7% | $9.48M-1.7% | ||
| $1.37B+21.8% | $1.32B+19.3% | $1.27B+16.5% | $1.23B+15.6% | $1.12B+3.3% | ||
| $274.31M+19.5% | $264.73M+19.3% | $246.17M+8.5% | $242.08M+11.8% | $229.47M+3.2% | ||
| $1.1B+22.4% | $1.06B+19.3% | $1.03B+18.6% | $985.66M+16.6% | $894.97M+3.3% | ||
| 24.6%+1.9pp | 24.6%+1.8pp | 24.7%+2.1pp | 24.4%+2.1pp | 22.8%-0.5pp | ||
| $13.59+25.6% | $13.08+22.6% | $12.61+21.7% | $12.01+19.0% | $10.82+4.8% | ||
| $13.70+25.5% | $13.18+22.3% | $12.72+21.5% | $12.12+18.9% | $10.92+4.7% | ||
| 322.9M-2.6% | 324.6M-2.7% | 326.8M-2.3% | 329.2M-1.8% | 331.6M-1.3% | ||
| 320.6M-2.5% | 322.3M-2.5% | 324.3M-2.1% | 326.5M-1.6% | 328.7M-1.1% | ||
| $2.39M-74.8% | $3.01M-76.3% | $4.62M-67.3% | $6.76M-46.7% | $9.48M-1.7% | ||
| $4.45B+13.1% | $4.3B+10.4% | $4.17B+8.4% | $4.04B+6.7% | $3.93B+5.6% | ||
| $1.55B+21.5% | $1.51B+19.6% | $1.45B+16.8% | $1.39B+15.7% | $1.28B+3.9% | ||
| 35%+2.4pp | 35%+2.7pp | 34.7%+2.5pp | 34.5%+2.7pp | 32.6%-0.5pp | ||
| $1.41B+22.7% | $1.36B+20.5% | $1.31B+17.5% | $1.26B+15.9% | $1.15B+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Idexx Laboratories's revenue?
- Idexx Laboratories (IDXX) generated $4.4B in revenue over the trailing twelve months, up 13.1% year over year.
- Is Idexx Laboratories profitable?
- Idexx Laboratories reported $1.1B in net income over the trailing twelve months, a 24.6% net margin.
- What are Idexx Laboratories's profit margins?
- Gross margin is 62.1% and operating margin is 31.6%, with a 24.6% net margin.
- What is Idexx Laboratories's earnings per share?
- Idexx Laboratories's diluted EPS over the trailing twelve months is $13.59.
- Where does Idexx Laboratories's income statement data come from?
- Every line is extracted from Idexx Laboratories's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
